한글목차

APT-1011은 Adare의 독자적인 AdvaTab 기술이 적용된 플루티카존의 새로운 경구용 제제로, 구강 내 체류 시간을 최소화하면서 식도에 국소적으로 전달할 가능성이 있습니다. APT-1011은 선행 임상에서 EoE 진단을 받은 성인의 식도 호산구 수와 내시경 소견을 효과적으로 감소시켰으며, 2019년 성공적인 임상 2상(FLUTE I)에 이어 현재 임상 3상(FLUTE II)을 진행하고 있습니다. 현재 임상 3상(FLUTE II)을 진행 중입니다.

앞으로 몇 년동안 호산구성 식도염(EoE) 시장 시나리오는 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것으로 예상됩니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, APT-1011의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, EoE에 대한 다른 신흥 제품들이 APT-1011과 치열한 시장 경쟁을 벌일 것으로 예상되고 있습니다. 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 APT-1011 시장에 대해 조사했으며, 시장 개요와 함께 2023-2032년까지의 매출 예측 데이터, 경쟁 구도, 국가별 동향 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 호산구성 식도염(EoE)용 APT-1011 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 APT-1011 시장 평가

• EoE용 APT-1011 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국의 EoE용 APT-1011 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

“"APT-1011 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about APT-1011 for eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the APT-1011 for EoE in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the APT-1011 for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the APT-1011 market forecast analysis for EoE in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary:

APT-1011, a novel, oral formulation of fluticasone incorporating Adare's proprietary AdvaTab technology, allows for topical delivery of the drug to the esophagus whilst minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 effectively reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. APT-1011 has received ODD from the FDA and EMA and FDT from FDA. It is currently in Phase III development (FLUTE II), following the successful completion of its Phase II study (FLUTE I) in 2019.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the APT-1011 description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
• Elaborated details on APT-1011 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the APT-1011 research and development activities in EoE across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around APT-1011.
• The report contains forecasted sales of APT-1011 for EoE till 2032.
• Comprehensive coverage of the late-stage emerging therapies for EoE.
• The report also features the SWOT analysis with analyst views for APT-1011 in EoE.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

APT-1011 Analytical Perspective by DelveInsight

In-depth APT-1011 Market Assessment

This report provides a detailed market assessment of APT-1011 for eosinophilic esophagitis (EoE) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

APT-1011 Clinical Assessment

The report provides the clinical trials information of APT-1011 for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence APT-1011 dominance.
• Other emerging products for EoE are expected to give tough market competition to APT-1011 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of APT-1011 in EoE.
• Our in-depth analysis of the forecasted sales data of APT-1011 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the APT-1011 in EoE.

Key Questions:

• What is the product type, route of administration and mechanism of action of APT-1011?
• What is the clinical trial status of the study related to APT-1011 in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the APT-1011 development?
• What are the key designations that have been granted to APT-1011 for EoE?
• What is the forecasted market scenario of APT-1011 for EoE?
• What are the forecasted sales of APT-1011 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to APT-1011 for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

Table of Contents

1. Report Introduction

2. APT-1011 Overview in EoE

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. APT-1011 Market Assessment

• 5.1. Market Outlook of APT-1011 in EoE
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of APT-1011 in the 7MM for EoE
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of APT-1011 in the United States for EoE
  • 5.3.2. Market Size of APT-1011 in Germany for EoE
  • 5.3.3. Market Size of APT-1011 in France for EoE
  • 5.3.4. Market Size of APT-1011 in Italy for EoE
  • 5.3.5. Market Size of APT-1011 in Spain for EoE
  • 5.3.6. Market Size of APT-1011 in the United Kingdom for EoE
  • 5.3.7. Market Size of APT-1011 in Japan for EoE

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options